<?xml version="1.0" encoding="UTF-8"?>
<p>Because adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) have a poor prognosis, there has been keen interest in exploring other therapeutic modalities [
 <xref rid="CIT0001" ref-type="bibr">1</xref>]. One such approach is to genetically modify autologous T cells to express a chimeric antigen receptor (CAR) that targets a specific tumor antigen [
 <xref rid="CIT0002" ref-type="bibr">2</xref>]. CAR-modified T cells targeting the B cell-specific antigen CD19 have been studied in several clinical trials and demonstrated high rates of complete remission in patients with relapsed or refractory B-ALL [
 <xref rid="CIT0003" ref-type="bibr">3â€“7</xref>]. Based on these encouraging results, a CAR T-cell product was recently approved by the US Food and Drug Administration for treatment of relapsed or refractory B-ALL in children and young adults.
</p>
